INSIGHTS ON CLINICAL TRIAL PARTNERING

• Developing Community-Based And Trial-Naïve Sites: The Real ROI

  Trial-naïve sites, when supported with infrastructure, training, and network integration, represent a critical yet underused opportunity to expand patient access and accelerate recruitment.

• The Defensiveness Trap In Vendor Selection And Management

  In clinical research, sponsor–vendor relationships are often framed as negotiations. Yet while both sides want to achieve a successful study, the process often becomes a tug-of-war.

• Medable's Japanese Clinical Trial Exceeds FPI Date And eCOA Adherence

  A top-10 global pharma company aimed to address eCOA adherence and patient enrollment challenges faced by clinical trial sites in Japan. Explore an initiative to enhance the patient and site experience.

• Oncology Clinical Trials Key Considerations: Planning For Success

  Chief Scientific Officer Gabriel Kremmidiotis and CEO Yvonne Lungershausen from Avance Clinical delve into key strategies for conducting successful early-phase oncology trials for biotechs.

• Overcoming Unexpected Obstacles In A Phase 1 Study

  1/29/2025

  Discover how the implementation of mobile vision clinics (MVCs) was used to enhance efficiency in a Phase 1 clinical trial.

• The Next Frontier In Early Phase Oncology Trials

  10/18/2024

  This session explores the pivotal role of First-in-Human and early phase oncology trials in drug development, emphasizing the importance of comprehensive planning for successful execution.

• Why The TrialKit Platform License Agreement Changes The Economics Of Clinical Trials

  2/24/2026

  A platform‑based pricing model removes change‑order friction, enabling predictable budgets and faster study adjustments. It supports operational agility and portfolio‑level efficiency as trials evolve.

• Building A Gold Standard Trial Experience In Japan

  4/4/2025

  Hear how Medable worked with a Japanese sponsor to elevate their trial experience, achieve >90% patient and site adherence, and beat their forecasted FPI date, creating new eCOA standards adopted across all the customer’s vendors.

• Advantages Of Sourcing Biosimilars Vs. Branded Biologics In Clinical Trials

  3/12/2026

  Evaluate biosimilar alternatives during clinical trial planning to reduce comparator drug costs and improve overall study efficiency without compromising trial integrity.